KAI Initiates Third Phase 2a Study to Develop KAI-1678 for the Treatment of Neuropathic Pain

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has initiated a third Phase 2a study of KAI-1678, a first-in-class, isozyme-selective, small peptide inhibitor of the epsilon protein kinase C p... [more]

View complete Press Release article